Vivace Therapeutics Appoints New Leadership Ahead of Phase 3 Mesothelioma Trial

Vivace Therapeutics has strengthened its executive team as it prepares to advance VT3989, the first TEAD inhibitor entering Phase 3 clinical trials for mesothelioma treatment.

26 Aug, 11:35 — 26 Aug, 11:35

Post Share

Sources

Showing 1 of 1 sources

morningstar3d ago

Vivace Therapeutics Strengthens Leadership Team as It Prepares to Advance VT3989, the First TEAD Inhibitor to enter Phase 3 Clinical Trials, as the Leading Treatment for Mesothelioma - Morningstar

Vivace Therapeutics Strengthens Leadership Team as It Prepares to Advance VT3989, the First TEAD Inhibitor to enter Phase 3 Clinical Trials, as the Leading Treatment for Mesothelioma Morningstar

Read full article →

PERSPECTA

PERSPECTA

Vivace Therapeutics Appoints New Leadership Ahead of Phase 3 Mesothelioma Trial

Sources

Vivace Therapeutics Strengthens Leadership Team as It Prepares to Advance VT3989, the First TEAD Inhibitor to enter Phase 3 Clinical Trials, as the Leading Treatment for Mesothelioma - Morningstar

Related Stories

India Bans Two Major Brands From Selling Hing Powder

OpenAI Terminates Partnership With Cursor Following SpaceX Acquisition

Fed Chair Warsh signals rate hikes as inflation stays elevated

College Dropout Turns Full-Time Pokémon Card Reseller With $7.8M in Sales

PERSPECTA